Abstract
Gene therapy and virotherapy are among the approaches currently used to treat malignant tumors. Gene therapy and virotherapy use a specific therapeutic gene that causes death in cancer cells. In early attempts at gene therapy, therapeutic genes were driven by ubiquitous promoters such as the CMV promoter, which induce non-specific toxicity to normal cells and tissues in addition to the cancer cells. Recently, novel cancer- and/ or tissue-specific promoter systems have been developed to target cancer cells but not normal cells including stem cells. In this review, we describe cancer and/or tissue-specific gene therapy systems for the treatment of cancer. In particular, we will discuss three systems for gene therapy and virotherapy: i) tissue-specific promoter systems, ii) cancer-specific promoter systems, and iii) oncolytic virotherapy. We will also discuss the major challenges of cancer-targeting vector systems and future directions in this area.
| Original language | English |
|---|---|
| Pages (from-to) | 3-10 |
| Number of pages | 8 |
| Journal | International Journal of Molecular Medicine |
| Volume | 25 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2010 |
Fingerprint
Keywords
- Adenovirus
- Gene therapy
- Specific promoter
- Virotherapy
ASJC Scopus subject areas
- Genetics
Cite this
Adenovirus-mediated cancer gene therapy and virotherapy. / Fukazawa, Takuya; Matsuoka, Junji; Yamatsuji, Tomoki; Maeda, Yutaka; Durbin, Mary L.; Naomoto, Yoshio.
In: International Journal of Molecular Medicine, Vol. 25, No. 1, 2010, p. 3-10.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Adenovirus-mediated cancer gene therapy and virotherapy
AU - Fukazawa, Takuya
AU - Matsuoka, Junji
AU - Yamatsuji, Tomoki
AU - Maeda, Yutaka
AU - Durbin, Mary L.
AU - Naomoto, Yoshio
PY - 2010
Y1 - 2010
N2 - Gene therapy and virotherapy are among the approaches currently used to treat malignant tumors. Gene therapy and virotherapy use a specific therapeutic gene that causes death in cancer cells. In early attempts at gene therapy, therapeutic genes were driven by ubiquitous promoters such as the CMV promoter, which induce non-specific toxicity to normal cells and tissues in addition to the cancer cells. Recently, novel cancer- and/ or tissue-specific promoter systems have been developed to target cancer cells but not normal cells including stem cells. In this review, we describe cancer and/or tissue-specific gene therapy systems for the treatment of cancer. In particular, we will discuss three systems for gene therapy and virotherapy: i) tissue-specific promoter systems, ii) cancer-specific promoter systems, and iii) oncolytic virotherapy. We will also discuss the major challenges of cancer-targeting vector systems and future directions in this area.
AB - Gene therapy and virotherapy are among the approaches currently used to treat malignant tumors. Gene therapy and virotherapy use a specific therapeutic gene that causes death in cancer cells. In early attempts at gene therapy, therapeutic genes were driven by ubiquitous promoters such as the CMV promoter, which induce non-specific toxicity to normal cells and tissues in addition to the cancer cells. Recently, novel cancer- and/ or tissue-specific promoter systems have been developed to target cancer cells but not normal cells including stem cells. In this review, we describe cancer and/or tissue-specific gene therapy systems for the treatment of cancer. In particular, we will discuss three systems for gene therapy and virotherapy: i) tissue-specific promoter systems, ii) cancer-specific promoter systems, and iii) oncolytic virotherapy. We will also discuss the major challenges of cancer-targeting vector systems and future directions in this area.
KW - Adenovirus
KW - Gene therapy
KW - Specific promoter
KW - Virotherapy
UR - http://www.scopus.com/inward/record.url?scp=70549110920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70549110920&partnerID=8YFLogxK
U2 - 10.3892/ijmm_00000306
DO - 10.3892/ijmm_00000306
M3 - Article
C2 - 19956895
AN - SCOPUS:70549110920
VL - 25
SP - 3
EP - 10
JO - International Journal of Molecular Medicine
JF - International Journal of Molecular Medicine
SN - 1107-3756
IS - 1
ER -